What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025Blood

Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows high complete response rates with blinatumomab in B-ALL, suggesting improved treatment options.

Pooled complete response rate was high at 92.7%, indicating blinatumomab's efficacy in treating B-cell acute lymphoblastic leukemia.
A total of 824 patients across clinical trials were analyzed, reinforcing blinatumomab's positive impact on treatment outcomes.
Using a meta-analysis approach, response rates and adverse events were compared between blinatumomab and control groups.
Findings support the use of blinatumomab as a promising option in adult B-ALL consolidation regimens with manageable toxicity.

Kakarala et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows high complete response rates with blinatumomab in B-ALL, suggesting improved treatment options.

Pooled complete response rate was high at 92.7%, indicating blinatumomab's efficacy in treating B-cell acute lymphoblastic leukemia.
A total of 824 patients across clinical trials were analyzed, reinforcing blinatumomab's positive impact on treatment outcomes.
Using a meta-analysis approach, response rates and adverse events were compared between blinatumomab and control groups.
Findings support the use of blinatumomab as a promising option in adult B-ALL consolidation regimens with manageable toxicity.

Kakarala et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark